PURPOSE: To evaluate whether oral Age-Related Eye Disease Study (AREDS/2) supplementation is associated with structural or functional disease progression over 24 months in patients with Macular Telangiectasia Type 2 (MacTel). METHODS: This post hoc analysis included 208 participants enrolled in two 24-month Phase 3 clinical trials of revakinagene taroretcel-lwey for MacTel (sham, n = 98; treated, n = 110). Consistent AREDS/2 exposure was defined by documented intake at baseline and month 24. The primary outcome was 24-month change in ellipsoid zone (EZ) area loss. Secondary outcomes included changes in reading speed, best-corrected visual acuity (BCVA), and aggregate retinal sensitivity. Non-randomized exposure was adjusted using a doubly robust framework combining inverse probability of treatment weighting (IPTW) and multivariable survey-weighted linear regression. RESULTS: In the sham cohort, AREDS/2 supplementation was not associated with statistically significant differences in 24-month EZ area loss (P = 0.258). In the treated cohort, an initial association with greater EZ area loss among AREDS/2 users (P = 0.032) became non-significant after full multivariable adjustment for age, sex, and diabetes status (P = 0.577). Secondary functional metrics showed no significant differences between groups across either cohort. CONCLUSIONS: AREDS/2 supplementation was not associated with meaningful differences in structural or functional MacTel progression over a 24-month period. These findings do not provide evidence that routine AREDS/2 supplementation slows EZ area loss or preserves visual function in this population.
Hatcher et al. (Tue,) studied this question.